A microscope revealed an unexpected clue to fighting one of the deadliest brain cancers: DNA that should have been tightly wound was coming apart. Brittney Lozzi, a graduate student at Baylor College of Medicine, noticed that tumor cells from mice on a methionine-restricted diet had chromatin—the coiled structure that packages DNA—appearing partially unraveled instead of its usual compact organization. This casual observation has blossomed into a discovery that could reshape how we think about treating glioma, an aggressive form of brain cancer that remains among the most difficult to defeat.
The findings, published in the Proceedings of the National Academy of Sciences, emerged from a simple question posed by Dr. Benjamin Deneen, a neurosurgery professor and director of the Center for Cancer Neuroscience at Baylor: if glioma cells are unusually dependent on methionine to survive and grow, what happens when you restrict their supply? Cancer cells, it turns out, cannot manufacture methionine on their own—it must come from diet—and they're voracious consumers of this amino acid, using it to fuel rapid growth and control which genes are switched on or off.
The team tested this hypothesis using mouse models of high-grade glioma, dividing them into two groups: one fed a normal diet and another given a methionine-restricted diet. The results were striking. Mice whose diets were low in methionine lived longer and their tumors grew significantly more slowly. But the real breakthrough came when Lozzi and her colleagues dug deeper into the mechanism. Methionine plays a critical role in providing methyl groups—chemical tags that cells use to mark DNA. When methionine was scarce, these marking patterns changed, destabilizing the chromatin structure and triggering cancer cell death.
The researchers focused on a protein called Hp1bp3, which normally keeps chromatin organized by suppressing histone demethylases—enzymes that strip away methyl tags and trigger chromatin unraveling. In their experiments, when the team removed or reduced Hp1bp3 alongside methionine restriction, something remarkable happened. Tumors became far more sensitive to the dietary change. With both conditions present—low methionine and loss of Hp1bp3—tumor growth was significantly reduced and animal survival improved even more dramatically than either intervention alone could achieve.
This synergistic effect hints at a new therapeutic approach: targeting both the nutrient availability cancer cells depend on and the proteins that help organize their genetic material. For patients battling glioma, a disease where treatment options remain frustratingly limited, this represents a genuine opening. The work also underscores how careful observation under the microscope—the kind of close-looking that science sometimes takes for granted—can unlock insights that reshape clinical possibilities.
Dr. Deneen and his collaborators, working across Baylor College of Medicine, the Duncan Neurological Research Institute at Texas Children's Hospital, and other institutions, have opened a new line of inquiry into how metabolism and cellular organization intersect in cancer. The next steps will involve translating these findings from mouse models toward human applications, but the foundation is now laid. Sometimes the biggest breakthroughs begin not with sophisticated theory, but with a scientist noticing something that looks wrong—and having the curiosity to ask why.